Patients with type 2 diabetes using SGLT2 inhibitors are at a significantly lower risk of pneumonia and pneumonia mortality versus those using DPP4 Iinhibitors, reveals a reent study. The study was published in the Journal of Clinical Endocrinology and Metabolism on 08 November 2021.
Diabetes patients are known to be at a higher risk of pneumonia and pneumonia mortality. Sodium glucose co-transporter 2 inhibitors (SGLT2is) are the latest class of glucose-lowerinf agents that have shown to reduce pneumonia risk in clinical trials. However, not much is known about the real-world effectiveness of SGLT2is on the risk of pneumonia.
For more information, log into:
[ Ссылка ]
Get the latest medical and heath news at medicaldialogues.in
Follow us on
Twitter: [ Ссылка ]
Facebook: [ Ссылка ]...
Instagram: [ Ссылка ]...
LinkedIn: [ Ссылка ]...
Website: [ Ссылка ]
